This study looks at how well a new weekly insulin called insulin icodec works compared to daily insulin treatments in people with Type 2 diabetes. The study will compare Awiqli, which contains insulin icodec, to other long-acting insulins like Tresiba, Lantus, Toujeo, and Levemir. These medications are given as injections under the skin.
The purpose is to see if taking insulin once a week works as well as taking it once a day for controlling blood sugar levels. The study will measure how well both treatments control blood sugar by checking HbA1c levels (a measure of average blood sugar) over 52 weeks. The medications will be given through pre-filled injection pens that patients can use at home.
During the study, participants will continue taking their other diabetes medications while adding either the weekly or daily insulin. The study will also look at how satisfied patients are with their treatment and how well they stick to their prescribed insulin schedule. Researchers will monitor participants for side effects, particularly episodes of very low blood sugar.
Germany 
Italy 
